Article
Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial).
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jun 2016
Kanai M, Kawaguchi T, Kotaka M, Shinozaki K, Touyama T, Manaka D, Ishigure K, Hasegawa J, Munemoto Y, Matsui T, Takagane A, Ishikawa H, Matsumoto S, Sakamoto J, Saji S, Yoshino T, Ohtsu A, Watanabe T, Matsuda F
Abstract excerpt
BACKGROUND: Peripheral sensory neuropathy (PSN) is a dose-limiting toxicity of oxaliplatin-based chemotherapy. Several genetic markers have been shown to predict oxaliplatin-induced PSN; however, results remain to be validated in a large-scale and prospective pharmacogenomics study. PATIENTS AND METHODS: Among 882 patients enrolled in the JFMC41-1001-C2 (JOIN trial), which was designed to investigate the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
